Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Biocept, Inc. - Common Stock (NQ: BIOC )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biocept, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Biocept Reports Second Quarter 2022 Financial Results
From Biocept, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers ASLAN Pharma (NASDAQ:ASLN) stock moved upwards by 13.7% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million. 
Via Benzinga
Biocept to Present at the LD Micro Main Event XV
From Biocept, Inc.
Via Business Wire
Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System
From Biocept, Inc.
Via Business Wire
Recap: Biocept Q4 Earnings
  Biocept (NASDAQ:BIOC) reported its Q4 earnings results on Wednesday, April 6, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
From Biocept, Inc.
Via Business Wire
Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
From Biocept, Inc.
Via Business Wire
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Biocept, Inc.
Via Business Wire
Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q
From Biocept, Inc.
Via Business Wire
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
From Biocept, Inc.
Via Business Wire
Biocept Appoints RSM as Independent Auditor
From Biocept, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 77 companies made new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 61 companies hit new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Biocept to Hold Business Strategy Conference Call Today
From Biocept, Inc.
Via Business Wire
Biocept's Return On Capital Employed Overview
According to Benzinga Pro data, during Q1, Biocept (NASDAQ:BIOC) posted sales of $19.95 million. Earnings were up 6.84%, but Biocept still reported an overall loss of $2.77 million. 
Via Benzinga
Biocept Reports First Quarter 2022 Financial Results
From Biocept, Inc.
Via Business Wire
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q
From Biocept, Inc.
Via Business Wire
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Biocept, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
Looking Into Biocept's Return On Capital Employed
Benzinga Pro data, Biocept (NASDAQ:BIOC) reported Q4 sales of $13.98 million. Earnings fell to a loss of $2.97 million, resulting in a 375.6% decrease from last quarter. 
Via Benzinga
Biocept Reports 2021 Fourth Quarter and Full Year Financial Results
From Biocept, Inc.
Via Business Wire
Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance
From Biocept, Inc.
Via Business Wire
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For March 31, 2022
Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.